Thomas A Dineen

This inventor holds 10 USPTO granted patents and 15 published patent applications and 1 EPO patent. Top assignee: Blueprint Medicines Corporation. Active years: 2020-2026.

USPTO Granted Patents = 10 (Patent Applications = 15)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 13)

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 8(Granted Patents)

Company Filing History:

10 out of 71

Blueprint Medicines Corporation

patents

Years Active: 2020-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662465 - EGFR inhibitors (2026-06-23),

2. 12655129 - Heterocyclic EGFR inhibitors for use in the treatment of cancer (2026-06-16),

3. 12552795 - PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES (2026-02-17),

4. 12448379 - Wild type kit inhibitors (2025-10-21),

5. 12202844 - MAP4K1 inhibitors (2025-01-21),

6. 12172983 - EGFR inhibitors (2024-12-24),

7. 12042495 - MAP4K1 inhibitors (2024-07-23),

8. 11718602 - EGFR inhibitors (2023-08-08),

9. 11534441 - MAP4K1 inhibitors (2022-12-27),

10. 10829493 - Compositions and methods for treating KIT- and PDGFRA-mediated diseases (2020-11-10),

Title: Innovator Thomas A. Dineen: Advancements in Cancer Treatment

Introduction

Thomas A. Dineen is a distinguished inventor based in Cambridge, MA, who has significantly contributed to the field of pharmaceuticals, specifically in cancer treatment. With a portfolio of six patents, his work focuses on innovative compounds that target critical pathways in disease progression.

Latest Patents

Among his notable inventions are patents concerning MAP4K1 inhibitors and EGFR inhibitors. The MAP4K1 inhibitor patent describes a compound characterized by a specific formula that exhibits potential therapeutic benefits by controlling MAP4K1 activity in patients. This discovery may provide new avenues for treating various diseases that benefit from this control. Additionally, his EGFR inhibitor patent presents a structurally defined compound aimed at treating cancer, representing a promising advancement in oncology.

Career Highlights

Thomas A. Dineen is currently associated with Blueprint Medicines Corporation, where he applies his expertise to drive innovations in the treatment of cancer. His work reflects a commitment to developing effective therapies that target previously elusive pathways, thereby enhancing the therapeutic landscape.

Collaborations

Throughout his career, Dineen has collaborated with prominent professionals in the field, including Jason D. Brubaker and Emanuele Perola. These collaborations have undoubtedly enriched the research environment and accelerated the development of novel therapeutic strategies.

Conclusion

In summary, Thomas A. Dineen is a notable inventor whose contributions to MAP4K1 and EGFR inhibition represent significant advancements in cancer treatment. His dedication to research and collaboration continues to inspire innovation in the pharmaceutical sector, promising a brighter future for patients fighting cancer.